Revive Therapeutics Ltd (RVVTF)
0.0132
0.00 (0.00%)
USD |
OTCM |
Jun 21, 15:21
Revive Therapeutics Enterprise Value: 4.525M for June 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 20, 2024 | 4.525M |
| June 18, 2024 | 3.883M |
| June 17, 2024 | 4.385M |
| June 14, 2024 | 4.224M |
| June 13, 2024 | 4.708M |
| June 12, 2024 | 4.779M |
| June 11, 2024 | 4.690M |
| June 10, 2024 | 4.510M |
| June 07, 2024 | 4.840M |
| June 06, 2024 | 5.331M |
| June 05, 2024 | 5.389M |
| June 04, 2024 | 5.407M |
| June 03, 2024 | 5.317M |
| May 31, 2024 | 5.174M |
| May 30, 2024 | 5.532M |
| May 29, 2024 | 5.604M |
| May 28, 2024 | 6.392M |
| May 24, 2024 | 6.572M |
| May 23, 2024 | 6.464M |
| May 22, 2024 | 5.944M |
| May 21, 2024 | 5.855M |
| May 20, 2024 | 5.317M |
| May 17, 2024 | 6.392M |
| May 16, 2024 | 6.374M |
| May 15, 2024 | 6.213M |
| Date | Value |
|---|---|
| May 14, 2024 | 6.715M |
| May 13, 2024 | 6.572M |
| May 10, 2024 | 6.392M |
| May 09, 2024 | 6.034M |
| May 08, 2024 | 6.446M |
| May 07, 2024 | 6.446M |
| May 06, 2024 | 6.356M |
| May 03, 2024 | 6.392M |
| May 02, 2024 | 6.034M |
| May 01, 2024 | 6.536M |
| April 30, 2024 | 6.894M |
| April 29, 2024 | 6.482M |
| April 26, 2024 | 6.751M |
| April 25, 2024 | 6.589M |
| April 24, 2024 | 6.93M |
| April 23, 2024 | 6.428M |
| April 22, 2024 | 6.804M |
| April 19, 2024 | 6.392M |
| April 18, 2024 | 6.392M |
| April 17, 2024 | 6.607M |
| April 16, 2024 | 6.428M |
| April 15, 2024 | 6.597M |
| April 12, 2024 | 6.392M |
| April 11, 2024 | 6.804M |
| April 10, 2024 | 6.858M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.050M
Minimum
Dec 13 2019
144.69M
Maximum
Jul 06 2021
46.54M
Average
34.88M
Median
Jan 19 2023
Enterprise Value Benchmarks
| Acasti Pharma Inc | 4.494M |
| Aurinia Pharmaceuticals Inc | 428.97M |
| Edesa Biotech Inc | 10.90M |
| Lexaria Bioscience Corp | 31.69M |
| Xenon Pharmaceuticals Inc | 2.100B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.388M |
| Total Expenses (Quarterly) | 1.376M |
| EPS Diluted (Quarterly) | -0.0036 |
| Earnings Yield | -101.9% |